Infectologia
Revisão sistemática de escopo | Motivos para a prescrição de antibióticos por tempo além do recomendado no ambiente hospitalar.
30 Mai, 2022 | 13:06hEstudo relata primeiro uso de antivirais em pacientes com varíola dos macacos.
27 Mai, 2022 | 13:45hComunicado de imprensa: Study reports first use of antivirals in monkeypox patients – Lancet
Estudo original: Clinical features and management of human monkeypox: a retrospective observational study in the UK – The Lancet Infectious Diseases
Comentário: Antiviral drug may limit monkeypox symptom duration, infectiousness – CIDRAP
Comentário de um dos autores no Twitter (fio – clique para saber mais)
Clinical features and management of human monkeypox: a retrospective observational study in the UK https://t.co/0nUtw3lEDn
— Jake Dunning (@OutbreakJake) May 24, 2022
Comentário de estudo | Grande estudo mostra que risco de COVID longa diminui apenas discretamente após a vacinação.
27 Mai, 2022 | 13:44hComentário: Long COVID risk falls only slightly after vaccination, huge study shows – Nature
Estudo original: Long COVID after breakthrough SARS-CoV-2 infection – Nature Medicine
Comentário do autor no Twitter (fio – clique para saber mais)
The latest from our team in @NatureMedicine
Does vaccination protect from #LongCovid?
Vaccines modestly reduce but do not eliminate risk of Long Covid @VAResearch @vahsrd @WUSTLmed @WUSTLnews @VREFSTL@Biostayan @BCBowe https://t.co/UEexmL8svS
A thread 🧵
— Ziyad Al-Aly, MD (@zalaly) May 25, 2022
Estudo de coorte | Trajetória dos sintomas de Covid longa após vacinação contra Covid-19.
27 Mai, 2022 | 13:41hTrajectory of long covid symptoms after covid-19 vaccination: community based cohort study – The BMJ
Editorial: Are vaccines a potential treatment for long covid? – The BMJ
Comunicado de imprensa: Vaccination after SARS-CoV-2 infection linked to a decrease in long covid symptoms – BMJ Newsroom
Comentário no Twitter
LONG COVID: Number of well controlled studies (controls means comparison group of 1) unvaccinated and 2) those who have never had COVID) that show vaccination works to reduce or eliminate long COVID symptoms increasing. BMJ below + biggest from Israel herehttps://t.co/jtZ6aoDmFA https://t.co/n5oDs0Zxe9
— Monica Gandhi MD, MPH (@MonicaGandhi9) May 19, 2022
Estudo de coorte | Proteção e queda da imunidade natural e híbrida ao SARS-CoV-2.
27 Mai, 2022 | 13:39hProtection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine
Editorial: Audio Interview: Waning Immunity against Covid-19
Comentário no Twitter
Protection against SARS-CoV-2 waned over time in both vaccinated and previously infected persons; an additional vaccine dose restored protection, find investigators from Israel. https://t.co/617uBmWu8l pic.twitter.com/yiDnBbCuQ5
— NEJM (@NEJM) May 25, 2022
Estudo de caso-controle e teste negativo: efetividade dos reforços vacinais homólogos e heterólogos contra a variante Ômicron da COVID-19.
27 Mai, 2022 | 13:38hDiretriz sobre intervenções para melhorar a cicatrização de úlceras no pé diabético.
27 Mai, 2022 | 13:32hRevisão | Mudança climática e risco de doenças infecciosas.
27 Mai, 2022 | 13:08hClimate Change and Cascading Risks from Infectious Disease – Infectious Diseases and Therapy
Comentário no Twitter
Climate change is adversely affecting the burden of infectious disease throughout the world, which is a health security threat
Fantastic 🆕💥💥Review @InfectDis_Ther
Climate Change and Cascading Risks from Infectious Disease #IDTwitter #MedEd #TwitteRx https://t.co/eU85fOZzN0 pic.twitter.com/T6VKXe1dCP— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) May 20, 2022
Sob licença de http://creativecommons.org/licenses/by-nc/4.0/
Efetividade da CoronaVac em crianças de 3 a 5 anos durante o surto da variante Ômicron do SARS-CoV-2 no Chile.
26 Mai, 2022 | 13:24hEstudo randomizado | Baricitinibe vs. dexametasona para adultos internados com COVID-19.
26 Mai, 2022 | 13:23h
Comentário no Twitter
💥Just Out
ACTT-4 Trial👉First Double Placebo-Controlled Double-Blind Randomized-Stratified Head-to-Head#DEXAMETHASONE vs #BARICITINIB for hospitalized pts w/#COVID19 Low/High-Flow/NIV
Relevant👉Patient Care/Public Health/Guidelines
Our results
👇https://t.co/4Tmue7HK7V
🧵1/4 pic.twitter.com/aF1Y7BAdu3— Andre Kalil, MD MPH (@DrAndreKalil) May 24, 2022